3Madaras-Kelly KJ, Ostergaard BE, Horde LB, et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model[J].Antimicrob Agents Chemother, 1996, 40(3):627.
7Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens[J]. Antimicrob Agents Chemother, 2001,45(1): 23.
二级参考文献7
1[1]Craig W A. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men[J]. Clin lnfect Dis, 1998, 26: 1-12.
2[2]Nightingale C H, Murakawa T, Ambrose P G, et al. Antimicrobial pharmacodynamics in theory and clinical practice[M]. New York: Marcel Dekker, InC. 2002. 385-408.
3[3]Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies[J]. Clin lnfect Dis, 2001, 33: 147-156.
4Bamonte F,Dionisotti S,Gamba M,et al.Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig[].Journal of Chemotherapy.1990
5Gilbert DN.Once-daily aminoglycoside therapy[].Antimicrobial Agents and Chemotherapy.1991
6Wood CA,Norton DR,Kohlhepp SJ,et al.The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess[].The Journal of Infectious Diseases.1988
